Last reviewed · How we verify

Flunarizine 5mg

Shalamar Institute of Health Sciences · FDA-approved active Small molecule Quality 5/100

Flunarizine 5mg is a Small molecule drug developed by Shalamar Institute of Health Sciences. It is currently FDA-approved. Also known as: Sibelium.

Flunarizine 5mg, marketed by Shalamar Institute of Health Sciences, is a drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a competitive advantage due to its current marketed status. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic nameFlunarizine 5mg
Also known asSibelium
SponsorShalamar Institute of Health Sciences
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Flunarizine 5mg

What is Flunarizine 5mg?

Flunarizine 5mg is a Small molecule drug developed by Shalamar Institute of Health Sciences.

Who makes Flunarizine 5mg?

Flunarizine 5mg is developed and marketed by Shalamar Institute of Health Sciences (see full Shalamar Institute of Health Sciences pipeline at /company/shalamar-institute-of-health-sciences).

Is Flunarizine 5mg also known as anything else?

Flunarizine 5mg is also known as Sibelium.

What development phase is Flunarizine 5mg in?

Flunarizine 5mg is FDA-approved (marketed).

Related